WO2013166952A1 - Substituted aminoquinazolines useful as kinases inhibitors - Google Patents
Substituted aminoquinazolines useful as kinases inhibitors Download PDFInfo
- Publication number
- WO2013166952A1 WO2013166952A1 PCT/CN2013/075244 CN2013075244W WO2013166952A1 WO 2013166952 A1 WO2013166952 A1 WO 2013166952A1 CN 2013075244 W CN2013075244 W CN 2013075244W WO 2013166952 A1 WO2013166952 A1 WO 2013166952A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- quinazolin
- oxy
- enamide
- tetrahydrofuran
- Prior art date
Links
- HJXMCBWXOJMSMC-HNNXBMFYSA-N C#Cc1cc(Nc2c(cc(c(O[C@@H]3COCC3)c3)N)c3ncn2)ccc1 Chemical compound C#Cc1cc(Nc2c(cc(c(O[C@@H]3COCC3)c3)N)c3ncn2)ccc1 HJXMCBWXOJMSMC-HNNXBMFYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is directed to inhibitors of kinase and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and metabolites thereof, the preparation method thereof, and the use of such compounds to treat kinase mediated diseases and conditions such as cancer.
- Protein kinases represent a large family of enzymes, which catalyze the phosphorylation of target protein substrates.
- the phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate. Due to their activity in numerous cellular processes, protein kinases have emerged as important therapeutic targets.
- Epidermal growth factor is a widely distributed growth factor that in cancer, can stimulate cancer-cell proliferation, block apoptosis, activate invasion and metastasis, and stimulate angiogenesis (Citri, et al, Nat. Rev. Mol. Cell. Biol. 7:505, 2006; Hynes, et al, Nat. Rev. Cancer 5:341, 2005).
- the EGF receptor (EGFPv or ErbB) is a transmembrane, tyrosine kinase receptor that belongs to a family of four related receptors. The majority of human epithelial cancers are marked by functional activation of growth factors and receptors of this family (Ciardiello, et al, New Eng. J. Med.
- the human epidermal growth factor receptor (HER) tyrosine kinase family consists of four structurally related cellular receptors: the epidermal growth factor receptor (EGFR; HER1), HER2 (ErbB2), HER3 (ErbB3), and HER4.
- EGFR epidermal growth factor receptor
- HER1 epidermal growth factor receptor 1
- HER2 ErbB2
- HER3 ErbB3
- Quinazolines are a known class of kinase inhibitors with utility for the treatment of cancer, angiogenesis disorders, and inflammatory disorders. To this end, attempts have been made to identify small molecules which act as protein kinase inhibitors.
- quinazoline derivatives (PCT WO 00177104; US20050250761 ; WO2004069791) have been described as HER kinase inhibitors.
- the present invention provides compounds of Formula I:
- R 1 and R 2 are independently selected from hydrogen, and Ci-C 3 alkyl; R 3 is selected from hydrogen, halogen, C C 3 alkyl, CN, and CF 3 .
- the present invention further provides pharmaceutical compositions comprising a compound of Formula I described above and a pharmaceutically acceptable carrier.
- the present invention further provides methods for regulating the kinase signaling transduction comprising administrating to a mammalian subject a therapeutically effective amount of any of the compounds of Formula I described above.
- R 1 and R 2 are independently selected from hydrogen, and Ci-C 3 alkyl
- R 3 is selected from hydrogen, halogen, Ci-C 3 alkyl, CN, and CF 3 .
- R or R is hydrogen. In other embodiments, both R
- R are methyl or ethyl. In other embodiments, R is F. In some embodiments,
- R is methyl. In other embodiments R is hydrogen. In the preferred embodiments,
- R and R are independently selected from the group consisting of methyl and ethyl; and R 3 is selected from the group consisting of hydrogen, methyl, CI, and F. In the most preferred embodiment, R and R are both ethyl; and R is hydrogen, methyl, CI, or F.
- the compound of Formula I is in the form of pharmaceutically acceptable salt. In some embodiments, the compound of Formula I is in the form of a solvate. In other embodiments, the compound of Formula I is in the form of a metabolite. In other embodiments, the compound of Formula I is in the form of a prodrug. In some embodiments, the compound of Formula I is a stereoisomer. In other embodiments, the compound of Formula I is a tautomer. In another embodiment, the deuterium enrichment in compounds of Formula I is at least about 1%. In certain embodiments, there are provided compounds without limitation selected from the group consisting of:
- the selected compound is in the form of pharmaceutically acceptable salt.
- the selected compound is in the form of a solvate.
- the selected compound is in the form of a metabolite.
- the selected compound is in the form of stereoisomer.
- the selected compound is a tautomer.
- the selected compound is in the form of a prodrug.
- the deuterium enrichment in the selected compounds is at least about 1%.
- the present invention provides (RS,E)-4- (diethylamino)-N-(4-((3-ethynylphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quin azolin-6-yl)but-2-enamide, (S,E)-4-(diethylamino)-N-(4-((3-ethynylphenyl) amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide; or (R,E)-4- (diethylamino)-N-(4-((3 -ethynylphenyl)amino)-7-((tetrahydrofuran-3 -yl)oxy)quin azolin-6-yl)but-2-enamide.
- the present invention provides pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
- the compositions are for the treatment of a disease regulated by a protein kinase.
- the compositions are for the treatment of a hyper-proliferative disorder.
- the pharmaceutical compositions are suitable for oral, parenteral, or intravenous administration.
- the compound(s) of Formula I are used to treat a subject by administering the compound(s) as a pharmaceutical composition.
- the compound(s) in one embodiment, are combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
- the present invention provides methods for regulating the kinase signaling transduction comprising administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
- a HER kinases (including all mutant kinases) mediated disorder comprises administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
- methods for inhibiting EGFR kinases comprises administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
- methods for treating neoplasia comprising administrating to a mammalian subject in need thereof, a therapeutically effective amount of a compound of Formula I.
- the neoplasia is selected from liver cancer, skin cancer, leukemias, colon carcinoma, renal cell carcinoma, gastrointestinal stromal cancer, solid tumor cancer, myeloma, breast cancer, pancreatic carcinoma, non-small cell lung cancer, non-hodgkin's lymphoma, hepatocellular carcinoma, thyroid cancer, bladder cancer, colorectal cancer, and prostate cancer.
- the neoplasia is skin cancer.
- the methods further comprise administering one or more anti-cancer agents.
- there are provided methods for treating or preventing a hyper-proliferative comprising administrating to a mammalian subject a therapeutically effective amount of a compound of Formula I.
- alkyl is intended to include linear, branched, cyclic hydrocarbon group, which may be unsubstituted or optionally substituted with one or more functional groups.
- C 1-C3 alkyl is intended to include C 1? C 2 and C 3 alkyl groups. Examples of alkyl include, but not limited to, methyl, ethyl, n-propyl, isopropyl, cyclopropyl.
- Alkyl may be substituted or unsubstituted.
- Illustrative substituted alkyl group include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, hydoxymethyl, methoxymethyl, 2-fluoroethyl, 2-methoxyethyl, etc.
- Halogen means fluorine, chlorine, bromine, and iodine.
- the invention also includes isotopically-labeled compounds of the invention, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as Deterium and carbon such as 13 C.
- Certain isotopically-labeled compounds of the invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability; for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
- a pharmaceutically acceptable when used with reference to a compound of Formula I is intended to refer to a form of the compound that is safe for administration to a subject.
- a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of Formula I which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
- FDA Food and Drug Administration
- derivative is broadly construed herein, and intended to encompass any salt of a compound of this invention, any ester of a compound of this invention, or any other compound, which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to the ability to modulate a kinase enzyme.
- metabolic means a physiologically active compound resulting from the metabolism of an inventive compound, when such compound is administered to a mammal. Metabolites of a compound may be identified using routine techniques known in the art.
- prodrug denotes a compound which upon administration to a subject or patient is capable of providing (directly or indirectly) a compound of this invention.
- examples of prodrugs would include esterified or hydroxylated compounds where the ester or hydroxyl groups would cleave in vivo, such as in the gut, to produce a compound according to Formula I.
- a "pharmaceutically-acceptable prodrug” as used herein denotes a prodrug, which is pharmaceutically acceptable.
- excipient denotes any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.
- “Diluent” and “adjuvant” are defined hereinafter.
- the terms “treat”, “treating,” “treatment,” and “therapy” as used herein refer to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy.
- Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
- the phrase "effective amount" is intended to quantify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.
- the effective amount in one embodiment, is administered in a single dosage form or in multiple dosage forms.
- the invention further encompasses "intermediate" compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all "intermediates" included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.
- New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
- such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.
- the compounds of this invention in some embodiments also are represented in multiple tautomeric forms.
- the invention expressly includes all tautomeric forms of the compounds described herein.
- the compounds in one embodiment also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention.
- the present invention provides compounds which are capable of modulating one or more signal transduction pathways comprising, but not limited to EGFR and/or ErbB2.
- modulating it is meant that the functional activity of the pathway (or a component of it) is changed in comparison to its normal activity in the absence of the compound. This effect includes any quality or degree of modulation, including, increasing, agonizing, augmenting, enhancing, facilitating, stimulating, decreasing, blocking, inhibiting, reducing, diminishing, antagonizing, etc.
- the compounds of the present invention can also modulate one or more of the following processes, including, but not limited to, e.g., cell growth (including, e.g., differentiation, cell survival, and/or proliferation), tumor cell growth (including, e.g., differentiation, cell survival, and/or proliferation), tumor regression, endothelial cell growth (including, e.g., differentiation, cell survival, and/or proliferation), angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth), and/or hematopoiesis (e.g., T- and B-cell development, dendritic cell development, etc.).
- cell growth including, e.g., differentiation, cell survival, and/or proliferation
- tumor cell growth including, e.g., differentiation, cell survival, and/or proliferation
- tumor regression including, e.g., differentiation, cell survival, and/or proliferation
- endothelial cell growth including, e.g., differentiation, cell survival, and/or proliferation
- angiogenesis blood vessel growth
- kinase activity it is meant a catalytic activity in which a gamma-phosphate from adenosine triphosphate (ATP) is transferred to an amino acid residue (e.g., serine, threonine, or tyrosine) in a protein substrate.
- ATP adenosine triphosphate
- a compound can modulate kinase activity, e.g., inhibiting it by directly competing with ATP for the ATP -binding pocket of the kinase, by producing a conformational change in the enzyme's structure that affects its activity (e.g., by disrupting the biologically-active three-dimensional structure), by binding to and locking the kinase in an inactive conformation, etc.
- the compounds defined in the present invention possess biological activity. These properties may be assessed, for example, using one or more of the procedures set out below.
- the compounds of the invention can be dosed or administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or in conjunction with other agents.
- the therapeutic agents can be formulated as separate compositions that are administered simultaneously or sequentially at different times, or the therapeutic agents can be given as a single composition.
- methods for treatment of androgen receptor-dependent or androgen receptor-mediated conditions or diseases, such as proliferative disorders, including cancer comprises administration to a mammal a compound of Formula I in combination with at least one additional agent selected, by way of example only, alemtuzumab, arsenic trioxide, asparaginase (pegylated or non-), bevacizumab, cetuximab, platinum-based compounds such as cisplatin, cladribine, daunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil, gemtuzumab, methotrexate, taxol, temozolomide, thioguanine, or classes of drugs including hormones (an antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues, interferons such as alpha interferon, nitrogen mustards such as busulfan or melphalan
- DMF means N,N-dimethylformamide.
- DCM means dichloromethane.
- DIPEA means diisopropyl ethylamine.
- THF means tetrahydrofuran.
- TEA means triethylamine.
- EA means ethyl acetate.
- EDC means l-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
- AST means aspartate aminotransferase.
- ALT means alanine aminotransferase.
- KI means Potassium Iodine.
- Step 1 (S)-N 4 -(3-ethynylphenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-
- the assay was performed using Kinase-Glo Plus luminescence kinase assay kit (Promega). It measures kinase activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated with the amount of kinase activity.
- the compounds were diluted in 10% DMSO and 5 ⁇ 1 of the dilution was added to a 50 ⁇ 1 reaction so that the final concentration of DMSO is 1% in all of reactions. All of the enzymatic reactions were conducted at 30 °C for 25 minutes.
- the 50 ⁇ 1 reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl 2 , 0.1 mg/ml BSA, 1 mM DTT, 0.2 mg/ml Poly (Glu, Tyr) substrate, 10 ⁇ ATP and EGFR (Table 2.3.1).
- 50 ⁇ of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was added to each reaction and incubate the plate for 5 minutes at room temperature. Luminescence signal was measured using a BioTek Synergy 2 microplate reader.
- the IC50 value was determined by the concentration causing a half-maximal percent activity.
- Enzyme assay (EGFR/T790M): Compounds 20 and compound 13 were both found to have potency (IC 50 ) ⁇ 100 nM.
- Table 1 lists compounds representative of the invention and their activity in cell assays.
- HI 975 cells were cultured in RPMI1640 containing 10% fetal bovine serum, 1% L-glutamine, 100 U/mL penicillinG and 100 ⁇ g/mL streptomycin. Cells in logarithmic growth phase were harvested and resuspended in l xPBS for implantation.
- Tumor xenografts were established by injecting tumor cells 5x l0 6 /mouse into the right flank by sc under sterile conditions. When the tumors reached an appropriate size (100-200 mm ), mice were randomized into 6 mice per group (8 mice in control group). The tumors were measured using a caliper in two dimensions, length (a), and width (b). Tumor volumes were estimated from measurements of two diameters of the individual tumors as follows:
- mice were practicsed euthanasia by cervical dislocation, the tumor tissue was collected first, then abdominal cavity was cut open, liver and spleen were excised, then weight after the gallblader was removed respectively. Organ weight between the treated versus the control groups were compared. Compound 20 and compound 13 showed good efficacy in the NCI-H1975 xenograft study.
- Compound 20 has much smaller body weight loss than compound 13 or Afatinib (Table 2).
- a representative protocol for the in vivo experiment to establish the subcutaneous A431 cell line xenograft model in nude mice and to evaluate the in vivo therapeutic efficacy of the compounds is similar to the protocol described for subcutaneous NCI-H 1975 cell line xenograft model in nude mice.
- Compound 20 has much smaller body weight loss than Afatinib (Table 4).
- sample solution 5.26 mg of Compound 13 or 6.24 mg of Compound 20 was added individually to 2 mL eppendorf tube (EP), followed by addition of 1 mL of pH 6.8 buffer solution (20 mM). The solution was shook for 2 minutes and left for 30 minutes at 25 ° C . After standing for 30 minutes, precipitate was formed in the bottom of the EP. The solutions was filtered through 0.2 um membrane filter, and then diluted by 50 times with water.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/399,510 US9388170B2 (en) | 2012-05-07 | 2013-05-07 | Substituted aminoquinazolines useful as kinases inhibitors |
CN201380023396.5A CN104350049B (en) | 2012-05-07 | 2013-05-07 | Substituted-amino quinazoline as inhibitors of kinases |
JP2015510624A JP2015515995A (en) | 2012-05-07 | 2013-05-07 | Substituted aminoquinazolines useful as kinase inhibitors |
EP13787119.0A EP2847186B1 (en) | 2012-05-07 | 2013-05-07 | Substituted aminoquinazolines useful as kinases inhibitors |
KR1020147033806A KR20150005698A (en) | 2012-05-07 | 2013-05-07 | Substituted aminoquinazolines useful as kinases inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261687981P | 2012-05-07 | 2012-05-07 | |
US61/687,981 | 2012-05-07 | ||
US201361848413P | 2013-01-04 | 2013-01-04 | |
US61/848,413 | 2013-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013166952A1 true WO2013166952A1 (en) | 2013-11-14 |
Family
ID=49550148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/075244 WO2013166952A1 (en) | 2012-05-07 | 2013-05-07 | Substituted aminoquinazolines useful as kinases inhibitors |
Country Status (6)
Country | Link |
---|---|
US (1) | US9388170B2 (en) |
EP (1) | EP2847186B1 (en) |
JP (1) | JP2015515995A (en) |
KR (1) | KR20150005698A (en) |
CN (1) | CN104350049B (en) |
WO (1) | WO2013166952A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766356A1 (en) * | 2011-10-12 | 2014-08-20 | Teligene Ltd. | Quinazoline derivatives as kinases inhibitors and methods of use thereof |
JP2017503020A (en) * | 2013-12-31 | 2017-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for the preparation of (E) -4-N, N-dialkylaminocrotonic acid in the form of an HX salt and its use for the synthesis of EGFR tyrosine kinase inhibitors |
WO2017117680A1 (en) * | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279135A (en) * | 2016-08-09 | 2017-01-04 | 浙江医药高等专科学校 | A kind of Benzoquinazole class tyrosine kinase inhibitor of thiophenesulfonyl amine structure |
CN106349230A (en) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | Benzo-quinazoline tyrosine kinase inhibitor with nitrothiophene sulfamide structure and application |
CN106349231A (en) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | Benzoquinazoline tyrosine kinase inhibitor containing halothiophene sulfonamide structure |
CN106317039A (en) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | Ethoxy benzo quinazoline type tyrosine kinase inhibitor containing thiophenesulfonyl structure, preparation method and application |
CN106317040A (en) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | Benzo quinazoline tyrosine kinase inhibitor containing thiophene-sulfonamide structure, preparation method and application |
CN113121372A (en) * | 2019-12-31 | 2021-07-16 | 精华制药集团南通有限公司 | Preparation method of novel quinazoline drug side chain |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077104A1 (en) | 2000-04-08 | 2001-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them |
WO2004069791A2 (en) | 2003-02-05 | 2004-08-19 | Warner-Lambert Company Llc | Preparation of substituted quinazolines |
US20050250761A1 (en) | 2004-05-06 | 2005-11-10 | Pfizer Inc | 4-Phenylamino-quinazolin-6-yl-amides |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20100240649A1 (en) | 2006-07-05 | 2010-09-23 | Hesheng Zhang | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors |
WO2011084796A2 (en) | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
WO2012136099A1 (en) * | 2011-04-02 | 2012-10-11 | 齐鲁制药有限公司 | 4-(substituted phenylamino)quinazoline derivative and preparation method therefor, pharmaceutical composition and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012531433A (en) * | 2009-06-25 | 2012-12-10 | メドリューション リミテッド | Substituted heterocyclic compounds as kinase inhibitors and their uses |
-
2013
- 2013-05-07 US US14/399,510 patent/US9388170B2/en active Active
- 2013-05-07 CN CN201380023396.5A patent/CN104350049B/en active Active
- 2013-05-07 KR KR1020147033806A patent/KR20150005698A/en not_active Application Discontinuation
- 2013-05-07 JP JP2015510624A patent/JP2015515995A/en active Pending
- 2013-05-07 WO PCT/CN2013/075244 patent/WO2013166952A1/en active Application Filing
- 2013-05-07 EP EP13787119.0A patent/EP2847186B1/en not_active Not-in-force
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077104A1 (en) | 2000-04-08 | 2001-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
WO2004069791A2 (en) | 2003-02-05 | 2004-08-19 | Warner-Lambert Company Llc | Preparation of substituted quinazolines |
US20050250761A1 (en) | 2004-05-06 | 2005-11-10 | Pfizer Inc | 4-Phenylamino-quinazolin-6-yl-amides |
US20100240649A1 (en) | 2006-07-05 | 2010-09-23 | Hesheng Zhang | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors |
WO2011084796A2 (en) | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
WO2012136099A1 (en) * | 2011-04-02 | 2012-10-11 | 齐鲁制药有限公司 | 4-(substituted phenylamino)quinazoline derivative and preparation method therefor, pharmaceutical composition and use thereof |
Non-Patent Citations (10)
Title |
---|
"The Peptides", vol. 3, 1981, ACADEMIC PRESS |
CIARDIELLO ET AL., NEW ENG. J. MED., vol. 358, 2008, pages 1160 |
CITRI ET AL., NAT. REV. MOL. CELL. BIOL., vol. 7, 2006, pages 505 |
FAMING ZHUANLI SHENQING GONGKAI SHUOMINGSHU, 19 September 2001 (2001-09-19) |
HYNES ET AL., NAT. REV. CANCER, vol. 5, 2005, pages 341 |
J.F.W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
See also references of EP2847186A4 * |
T.W. GREENE: "Protective Groups in Organic Synthesis", 1981, WILEY |
TETRAHEDRON LETTERS, vol. 42, no. 46, 2001, pages 8141 - 8142 |
TETRAHEDRON, vol. 64, no. 44, 2008, pages 10195 - 10200 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766356A1 (en) * | 2011-10-12 | 2014-08-20 | Teligene Ltd. | Quinazoline derivatives as kinases inhibitors and methods of use thereof |
JP2014532063A (en) * | 2011-10-12 | 2014-12-04 | テリジェン リミテッドTeligene Ltd | Quinazoline derivatives as kinase inhibitors and methods of use thereof |
EP2766356A4 (en) * | 2011-10-12 | 2015-03-25 | Teligene Ltd | Quinazoline derivatives as kinases inhibitors and methods of use thereof |
JP2017503020A (en) * | 2013-12-31 | 2017-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for the preparation of (E) -4-N, N-dialkylaminocrotonic acid in the form of an HX salt and its use for the synthesis of EGFR tyrosine kinase inhibitors |
WO2017117680A1 (en) * | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US20150126539A1 (en) | 2015-05-07 |
EP2847186A1 (en) | 2015-03-18 |
JP2015515995A (en) | 2015-06-04 |
KR20150005698A (en) | 2015-01-14 |
EP2847186B1 (en) | 2017-08-09 |
US9388170B2 (en) | 2016-07-12 |
CN104350049A (en) | 2015-02-11 |
EP2847186A4 (en) | 2015-10-28 |
CN104350049B (en) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9388170B2 (en) | Substituted aminoquinazolines useful as kinases inhibitors | |
US9550738B2 (en) | Bicyclic compounds as kinases inhibitors | |
US9353062B2 (en) | Substituted quinolines as bruton's tyrosine kinases inhibitors | |
KR101668931B1 (en) | Effect potentiator for antitumor agents | |
JP2017525685A (en) | Pyridinylaminopyrimidine derivative, method for producing the same, and use thereof | |
EP2999702A1 (en) | Substituted pyrazolopyrimidines as kinases inhibitors | |
EP3181553B1 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
EP3102571B1 (en) | Substituted pyrimidines useful as egfr-t790m kinase inhibitors | |
JP2014521613A (en) | Quinazoline derivative, production method thereof, intermediate, composition and application thereof | |
US9388160B2 (en) | Quinazoline derivatives as kinases inhibitors and methods of use thereof | |
CN103965175A (en) | 4-(substituted phenylamino)quinazoline compounds, and preparation method and application thereof | |
US10173995B2 (en) | Pyridine compounds used as PI3 kinase inhibitors | |
JP7223684B2 (en) | Antitumor effect enhancer using pyrazolo[3,4-d]pyrimidine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13787119 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015510624 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14399510 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013787119 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013787119 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147033806 Country of ref document: KR Kind code of ref document: A |